{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:27Z","timestamp":1791312087823,"version":"4.3.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Blinatumomab, a bispecific T-cell engager, has demonstrated substantial clinical benefits in treating pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL). Approved by FDA for several indications, blinatumomab is now integral to therapeutic protocols for specific pediatric cohorts, with real-world applications steadily increasing. As one of the representatives of cutting-edge immunotherapy for pediatric ALL, blinatumomab plays a crucial role in precision medicine against the backdrop of current genetic testing. Clinical efficacy is influenced by factors such as tumor burden, endogenous T-cell function, CD19 antigen loss, and lineage switch. Treatment-related complications, such as cytokine release syndrome (CRS), neurotoxicity (ICANS), and infections, necessitate vigilant monitoring. Administration involves continuous intravenous infusion, with consideration for drug interactions. Despite proven short-term efficacy and tolerability, long-term impacts on pediatric patients warrant further investigation. Current studies refine dosing strategies and combinational approaches to enhance therapeutic precision for pediatric patients. This review synthesizes selected literature related to clinical trials of blinatumomab, emphasizing determinants of clinical efficacy and adverse events associated with treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1611701","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:14:42Z","timestamp":1753244082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Blinatumomab in pediatric B-acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Yifang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/jnci\/91.12.1051","article-title":"Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States","volume":"91","author":"Linet","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1182\/blood.v90.11.4243","article-title":"Fifty years of studies of the biology and therapy of childhood leukemia","volume":"90","author":"Kersey","year":"1997","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/jco.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/srep04227","article-title":"Survival improvement by decade of patients aged 0\u201314 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma","year":"2014","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122544","article-title":"Blinatumomab in pediatric acute lymphoblastic leukemia\u2014 from salvage to first line therapy (A systematic review)","volume":"10","author":"Queudeville","year":"2021","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3760\/cma.j.cn101070-20230515-00382","article-title":"Research progress of acute lymphoblastic leukemia with TP53 gene mutation","volume":"39","author":"Yin","year":"2024","journal-title":"Chin J Pract Pediatr Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.210104","article-title":"Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation","volume":"104","author":"Mouttet","year":"2019","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1032664","article-title":"Efficacy and safety of blinatumomab in children with relapsed\/refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B13","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Pediatric Acute Lymphoblastic Leukemia (Version 2.2025)","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20240528-00194","article-title":"Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)","volume":"45","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15721581","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29852","article-title":"Blinatumomab with donor lymphocyte infusions post haploidentical hematopoietic stem cell transplantation as salvage therapy for relapsed refractory acute lymphoblastic leukemia post chimeric antigen receptor T-cell therapy","volume":"70","author":"Chan","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27898","article-title":"Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia","volume":"66","author":"Elitzur","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1034373","article-title":"Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study","volume":"10","author":"Wu","year":"2022","journal-title":"Front Pediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01791-1","article-title":"Blinatumomab bridge therapy for mitigating chemotoxicity in children with acute lymphoblastic leukemia","volume":"40","author":"Yozgat","year":"2024","journal-title":"Indian J Hematol Blood Transfusion"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101095","DOI":"10.1016\/j.beha.2019.101095","article-title":"How advanced are we in targeting novel subtypes of ALL","volume":"32","author":"Mullighan","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14474","article-title":"Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics","volume":"176","author":"Tasian","year":"2017","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2020.10.013","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities","volume-title":"Seminars in Cancer Biology","author":"Tran","year":"2022"},{"key":"B23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12967-025-06399-1","article-title":"Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"23","author":"Cao","year":"2025","journal-title":"J Trans Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome - Positive acute lymphoblastic leukemia: A Children\u2019s Oncology Group Study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B26","volume-title":"WHO Classification of Tumours: Haematolymphoid Tumours","year":"2022"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006649","article-title":"Intrinsic suppression of type i interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia","volume":"11","author":"Kumar","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019000962","article-title":"Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia","volume":"136","author":"Ferrari","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19104","article-title":"Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study","volume":"203","author":"Ocadlikova","year":"2023","journal-title":"Br J Haematology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.098741","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283818","article-title":"Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia","volume-title":"Haematologica","author":"Lyons","year":"2024"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.06.015","article-title":"Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"44","author":"Shi","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7499\/j.issn.1008-8830.2210114","article-title":"Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed\/refractory acute lymphoblastic leukemia","volume":"25","author":"Li","year":"2023","journal-title":"Chin J Contemp Pediatr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20231127-00283","article-title":"Clinical efficacy and safety of blinatumomab bridging CAR- T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia","volume":"45","author":"Pu","year":"2024","journal-title":"Chin J Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-021-07435-2","article-title":"Blinatumomab-induced T cell activation at single cell transcriptome resolution.","volume":"22","author":"Huo","year":"2021","journal-title":"BMC Genomics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124636","article-title":"Blinatumomab-induced t cell activation at single cell transcriptome resolution","volume":"134","author":"Yin","year":"2019","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2230888","article-title":"Blinatumomab as salvage therapy in patients with relapsed\/refractory B-ALL who have failed\/progressed after anti-CD19-CAR T therapy","volume":"55","author":"Qi","year":"2023","journal-title":"Ann Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2232496","article-title":"Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review","volume":"64","author":"Locatelli","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23074019","article-title":"Lineage conversion in pediatric B-Cell precursor acute leukemia under blinatumomab therapy","volume":"23","author":"Semchenkova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2019.01.011","article-title":"Immunotherapy in pediatric B-cell acute lymphoblastic leukemia","volume-title":"Human Immunology","author":"Wyatt","year":"2019"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume-title":"Biology of Blood and Marrow Transplantation","author":"Lee","year":"2019"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21583","article-title":"Cytokine release syndrome following blinatumomab therapy","volume":"14","author":"Ojemolon","year":"2022","journal-title":"Cureus"},{"key":"B51","doi-asserted-by":"publisher","first-page":"41344140","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.929122","article-title":"The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"10","author":"Marrapodi","year":"2022","journal-title":"Front Pediatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:14:49Z","timestamp":1753244089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2025.1611701"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1611701","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"article-number":"1611701"}}